Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

British Heart Journal logoLink to British Heart Journal
. 1995 Dec;74(6):660–663. doi: 10.1136/hrt.74.6.660

Appetite suppressants and primary pulmonary hypertension in the United Kingdom.

S H Thomas 1, A Y Butt 1, P A Corris 1, J J Egan 1, T W Higenbottam 1, B P Madden 1, P C Waller 1
PMCID: PMC484125  PMID: 8541174

Abstract

OBJECTIVE--Amphetamine-like appetite suppressants, particularly fenfluramines, have been implicated in the aetiology of primary pulmonary hypertension. At one specialist centre in France 20% of patients with primary pulmonary hypertension had been exposed to fenfluramine. The prevalence of primary pulmonary hypertension associated with fenfluramines and other appetite suppressants in the United Kingdom is unknown. This study was performed to measure prior exposure to appetite suppressants in patients with primary pulmonary hypertension. SETTING--Heart lung transplantation centres in England. PATIENTS--United Kingdom residents with proven primary pulmonary hypertension referred for consideration of heart lung transplantation. METHODS--Case surveillance study, obtaining data from the hospital and general practitioner's notes and directly from the patients or their relatives. RESULTS--55 patients were identified. Drug histories were available from hospital records in all patients, from the general practitioner's notes in 51, and from the patients or relatives in 44. Of these, 3 female patients had been exposed to appetite suppressants (2 fenfluramine, 1 diethylpropion): 2 have since died. In each case exposure was brief and apparently predated the development of symptoms by several years. CONCLUSIONS--Exposure of patients with severe primary pulmonary hypertension to fenfluramine and other appetite suppressants is uncommon in the United Kingdom unlike in France, where most of the cases associating primary pulmonary hypertension with fenfluramine use have originated. This may reflect more conservative prescribing of these agents in the United Kingdom.

Full text

PDF
660

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atanassoff P. G., Weiss B. M., Schmid E. R., Tornic M. Pulmonary hypertension and dexfenfluramine. Lancet. 1992 Feb 15;339(8790):436–436. [PubMed] [Google Scholar]
  2. Bradley J. D., Zanaboni P. B., Dahms T. E. Species differences in pulmonary vasoactive responses to histamine, 5-hydroxytryptamine, and KCl. J Appl Physiol (1985) 1993 Jan;74(1):139–146. doi: 10.1152/jappl.1993.74.1.139. [DOI] [PubMed] [Google Scholar]
  3. Brenot F., Herve P., Petitpretz P., Parent F., Duroux P., Simonneau G. Primary pulmonary hypertension and fenfluramine use. Br Heart J. 1993 Dec;70(6):537–541. doi: 10.1136/hrt.70.6.537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Butt A. Y., Higenbottam T. New therapies for primary pulmonary hypertension. Chest. 1994 Feb;105(2 Suppl):21S–25S. doi: 10.1378/chest.105.2_supplement.21s. [DOI] [PubMed] [Google Scholar]
  5. Cameron J., Waugh L., Loadsman T., White P., Radford D. J. Possible association of pulmonary hypertension with an anorectic drug. Med J Aust. 1984 May 12;140(10):595–597. doi: 10.5694/j.1326-5377.1984.tb108427.x. [DOI] [PubMed] [Google Scholar]
  6. Douglas J. G., Munro J. F., Kitchin A. H., Muir A. L., Proudfoot A. T. Pulmonary hypertension and fenfluramine. Br Med J (Clin Res Ed) 1981 Oct 3;283(6296):881–883. doi: 10.1136/bmj.283.6296.881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fahlén M., Bergman H., Helder G., Rydén L., Wallentin I., Zettergren L. Phenformin and pulmonary hypertension. Br Heart J. 1973 Aug;35(8):824–828. doi: 10.1136/hrt.35.8.824. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Follath F., Burkart F., Schweizer W. Drug-induced pulmonary hypertension? Br Med J. 1971 Jan 30;1(5743):265–266. doi: 10.1136/bmj.1.5743.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gaul G., Blazek G., Deutsch E., Heeger H. Ein Fall von chronischer pulmonaler Hypertonie nach Fenfluramineinnahme. Wien Klin Wochenschr. 1982 Nov 26;94(22):618–622. [PubMed] [Google Scholar]
  10. Hunsinger R. N., Wright D. A characterization of the acute cardiopulmonary toxicity of fenfluramine in the rat. Pharmacol Res. 1990 May-Jun;22(3):371–378. doi: 10.1016/1043-6618(90)90735-v. [DOI] [PubMed] [Google Scholar]
  11. Kay J. M., Smith P., Heath D. Aminorex and the pulmonary circulation. Thorax. 1971 May;26(3):262–270. doi: 10.1136/thx.26.3.262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kleiger R. E., Boxer M., Ingham R. E., Harrison D. C. Pulmonary hypertension in patients using oral contraceptives. A report of six cases. Chest. 1976 Feb;69(2):143–147. doi: 10.1378/chest.69.2.143. [DOI] [PubMed] [Google Scholar]
  13. Loogen F., Worth H., Schwan G., Goeckenjan G., Lösse B., Horstkotte D. Long-term follow-up of pulmonary hypertension in patients with and without anorectic drug intake. Cor Vasa. 1985;27(2-3):111–124. [PubMed] [Google Scholar]
  14. Malmquist J., Trell E., Torp A., Lindström C. A case of drug-induced (?) pulmonary hypertension. Acta Med Scand. 1970 Oct;188(4):265–272. doi: 10.1111/j.0954-6820.1970.tb08035.x. [DOI] [PubMed] [Google Scholar]
  15. McMurray J., Bloomfield P., Miller H. C. Irreversible pulmonary hypertension after treatment with fenfluramine. Br Med J (Clin Res Ed) 1986 Jan 25;292(6515):239–240. doi: 10.1136/bmj.292.6515.239-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Nall K. C., Rubin L. J., Lipskind S., Sennesh J. D. Reversible pulmonary hypertension associated with anorexigen use. Am J Med. 1991 Jul;91(1):97–99. doi: 10.1016/0002-9343(91)90082-9. [DOI] [PubMed] [Google Scholar]
  17. Neely C. F., Haile D., Matot I. Tone-dependent responses of 5-hydroxytryptamine in the feline pulmonary vascular bed are mediated by two different 5-hydroxytryptamine receptors. J Pharmacol Exp Ther. 1993 Mar;264(3):1315–1326. [PubMed] [Google Scholar]
  18. Pouwels H. M., Smeets J. L., Cheriex E. C., Wouters E. F. Pulmonary hypertension and fenfluramine. Eur Respir J. 1990 May;3(5):606–607. [PubMed] [Google Scholar]
  19. Roche N., Labrune S., Braun J. M., Huchon G. J. Pulmonary hypertension and dexfenfluramine. Lancet. 1992 Feb 15;339(8790):436–437. [PubMed] [Google Scholar]
  20. Turner P. Dexfenfluramine. Its place in weight control. Drugs. 1990;39 (Suppl 3):53–62. doi: 10.2165/00003495-199000393-00007. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES